Capricor Therapeutics (CAPR) Tops Q3 EPS by 27c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.43), $0.27 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $142.1 thousand versus the consensus estimate of $200 thousand.

As of September 30, 2019, the Company’s cash, cash equivalents and marketable securities totaled approximately $6.8 million compared to approximately $7.3 million on December 31, 2018. Additionally, so far in the third quarter of 2019, Capricor has raised approximately $2.6 million in net proceeds at an average price of approximately $3.81 per share under its at-the-market offering programs.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance